|Articles|July 6, 2015

Top 6 Reasons for Phase III Trial Failures

. .

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Spinogenix Receives Positive FDA Feedback for SPG601 in Fragile X Syndrome
September 5th 2025
Driving Data Innovation and AI Adoption in Clinical Trials: A Q&A with Novo Nordisk’s VP of Data Systems Innovation
September 5th 2025
How AI Can Help Physicians Identify Eligible Trials Faster
September 5th 2025
$Epkinly Demonstrates Encouraging Efficacy in Phase II Trial for Relapsed or Refractory Diffuse Large B-Cell Lymphoma$
Epkinly Demonstrates Encouraging Efficacy in Phase II Trial for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
September 4th 2025
Promising Trial Data Leads to Breakthrough Designation for Eli Lilly’s Investigational KRAS G12C Inhibitor in Advanced, Metastatic Non-Small Cell Lung Cancer
September 4th 2025
Leqvio Shows Clinically Meaningful LDL-C Goal Attainment in Patients with Hypercholesterolemia in Phase IV Trial
September 4th 2025

Top 6 Reasons for Phase III Trial Failures

Newsletter

Related Articles